News
Public · Published
Moderna swings to Q3 profit, raises outlook on strong COVID vaccine demand
Moderna reported third-quarter revenue growth of 29% year over year, driven mainly by higher international COVID vaccine sales. It returned to net profit, and adjusted earnings per share beat analyst expectations. The company raised its 2026 revenue growth outlook to 15%–25%, from up to 10%.
Published:
Updated:
What happened
Moderna reported third-quarter revenue growth of 29% year over year, driven mainly by higher international COVID vaccine sales. It returned to net profit, and adjusted earnings per share beat analyst expectations. The company raised its 2026 revenue growth outlook to 15%–25%, from up to 10%.
Confirmed
Global impact / market context
Higher vaccine sales and lower research and development costs helped Moderna return to profit, while the stronger outlook suggests management expects revenue to keep growing. That could support investment in its vaccine portfolio, but projected costs and future demand will affect cash available.
Analyst inference
The reported growth came mainly from international COVID vaccine sales, including deliveries under long-term government partnerships, rather than evidence of broad demand across all products. Moderna also cited portfolio expansion and lower development costs, so investors will need to distinguish recurring sales from temporary cost reductions.
Analyst inference
What to watch
- Watch whether international COVID vaccine sales continue growing, since higher sales in those markets were the main stated driver of third-quarter revenue growth. Analyst inference
- Compare 2026 revenue growth with the raised 15%–25% outlook, and assess whether new approvals for respiratory vaccines help expand sales. Analyst inference
- Track whether 2026 cost of sales and year-end cash and investments match company projections; the cash estimate rose from the prior forecast range. Analyst inference
Evidence
- Original source link unavailable